Significant differences in treatment mechanisms and indications between trifluridine, tipiracil (Lancever) and bevacizumab

Trifluridine, tipiracil (Lonsurf) and bevacizumab (Bevacizumab) have obvious differences in their modes of action and application scenarios in the treatment of cancer. Trifluridine and tipiracil fight cancer by directly inhibiting the proliferation of cancer cells; while bevacizumab indirectly inhibits tumor growth by cutting off the tumor's nutrient supply.

Trifluridine and tipiracil are mainly used to treat some malignant tumors of the digestive system, especially colorectal cancer and gastric cancer. As a representative of fluorouracil drugs, it effectively interferes with the DNA replication process by precisely inhibiting the synthesis of deoxyuridylic acid, thereby achieving strong suppression of cancer cells. The tipiracil component further strengthens the effect of fluorouracil and provides a double guarantee for reducing the proliferation of cancer cells by inhibiting thymidine kinase. In clinical practice, trifluridine and tipiracil are often used in combination with other anticancer drugs in order to achieve better therapeutic effects.

Bevacizumab is a high-profile targeted therapy drug, which is also known as an anti-angiogenic drug or VEGF antibody. The VEGF mentioned here, vascular endothelial growth factor, is a powerful assistant in tumor growth and spread. It continuously provides nutrients by laying a blood vessel network for cancer cells. By binding to VEGF and neutralizing its activity, bevacizumab effectively cuts off the nutrient supply to the tumor, severely curbing tumor growth. Because of its unique anti-angiogenic mechanism, bevacizumab plays an important role in the treatment of a variety of solid tumors, especially those with rich blood vessels, such as non-small cell lung cancer, colorectal cancer, and renal cancer. It has shown significant therapeutic effects.